Anand Patel
@anand-88-patel.bsky.social
Leukemia & myeloid malignancy doctor. posts=mine. Repost≠endorsement. He/him. https://scholar.google.com/citations?user=kNhjy-MAAAAJ&hl=en
Pinned
Check our work on disparities in MF outcomes led by @andrewthepalmer.bsky.social! We found:
-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well
www.nature.com/articles/s41...
-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well
www.nature.com/articles/s41...
a thoughtful @bloodjournal.bsky.social article on recent negative Phase III studies in higher-risk MDS
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
November 14, 2025 at 1:27 AM
a thoughtful @bloodjournal.bsky.social article on recent negative Phase III studies in higher-risk MDS
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Our NCI study of HMA +/- Iadademstat is enrolling briskly for patients with HMA-naive accelerated/blast phase MPNs and overlap syndromes!
www.cancer.gov/research/par...
www.cancer.gov/research/par...
November 11, 2025 at 11:49 PM
Our NCI study of HMA +/- Iadademstat is enrolling briskly for patients with HMA-naive accelerated/blast phase MPNs and overlap syndromes!
www.cancer.gov/research/par...
www.cancer.gov/research/par...
excited to be able to highlight our Myelomatch study for IDH2-mutated MDS at the ongoing Alliance meeting!
November 7, 2025 at 6:57 PM
excited to be able to highlight our Myelomatch study for IDH2-mutated MDS at the ongoing Alliance meeting!
Very excited to be sharing the results of our Phase II trial of TKI plus inotuzumab for Ph+ ALL as an oral presentation at the @ash.hematology.org annual meeting!
November 3, 2025 at 2:56 PM
Very excited to be sharing the results of our Phase II trial of TKI plus inotuzumab for Ph+ ALL as an oral presentation at the @ash.hematology.org annual meeting!
Fall colors are out in Chicago!
November 2, 2025 at 4:42 PM
Fall colors are out in Chicago!
Congrats to @andrewthepalmer.bsky.social on his @ash.hematology.org Abstract Achievement Award!
www.hematology.org/awards/award...
www.hematology.org/awards/award...
2025 - Hematology.org
2025
www.hematology.org
November 1, 2025 at 9:20 PM
Congrats to @andrewthepalmer.bsky.social on his @ash.hematology.org Abstract Achievement Award!
www.hematology.org/awards/award...
www.hematology.org/awards/award...
excellent paper in @bloodjournals.hematology.org on the role of RAS in resistance to FLT3-inhibition and BCL2 inhibition in AML and the potential role of RAS inhibition
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
October 30, 2025 at 7:26 PM
excellent paper in @bloodjournals.hematology.org on the role of RAS in resistance to FLT3-inhibition and BCL2 inhibition in AML and the potential role of RAS inhibition
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Thrilled to share work on outcomes of pts with acute leukemia that previously received revumenib! In 15 pts that received post-rev therapy we found:
-11 pt got Ven-containing regimens (6 HMA-VEN, 5 IC-VEN)
-CR/CRi rate of 47%
-6 pts were bridged to allo-HCT
onlinelibrary.wiley.com/doi/10.1111/...
-11 pt got Ven-containing regimens (6 HMA-VEN, 5 IC-VEN)
-CR/CRi rate of 47%
-6 pts were bridged to allo-HCT
onlinelibrary.wiley.com/doi/10.1111/...
October 27, 2025 at 12:11 PM
Thrilled to share work on outcomes of pts with acute leukemia that previously received revumenib! In 15 pts that received post-rev therapy we found:
-11 pt got Ven-containing regimens (6 HMA-VEN, 5 IC-VEN)
-CR/CRi rate of 47%
-6 pts were bridged to allo-HCT
onlinelibrary.wiley.com/doi/10.1111/...
-11 pt got Ven-containing regimens (6 HMA-VEN, 5 IC-VEN)
-CR/CRi rate of 47%
-6 pts were bridged to allo-HCT
onlinelibrary.wiley.com/doi/10.1111/...
October 25, 2025 at 1:06 AM
Reposted by Anand Patel
ICE's arrest of a teen cancer patient's father is "unconscionable," officials say as they demand his release. blockclubchi.co/4hruJlW
October 24, 2025 at 2:01 AM
ICE's arrest of a teen cancer patient's father is "unconscionable," officials say as they demand his release. blockclubchi.co/4hruJlW
excellent article in @bloodjournals.hematology.org on the challenges of incorporating novel therapies into the routine management of ALL!
ashpublications.org/bloodadvance...
ashpublications.org/bloodadvance...
October 21, 2025 at 12:15 PM
excellent article in @bloodjournals.hematology.org on the challenges of incorporating novel therapies into the routine management of ALL!
ashpublications.org/bloodadvance...
ashpublications.org/bloodadvance...
Thank you to the Mumbai Hematology Group for virtually inviting me to speak about accelerated/blast-phase MPNs!
October 18, 2025 at 2:24 PM
Thank you to the Mumbai Hematology Group for virtually inviting me to speak about accelerated/blast-phase MPNs!
Proud to be a part of this effort in @bloodjournals.hematology.org led by Andrew Hantel looking at the impact of inclusion criteria for AML clinical trials!
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
October 16, 2025 at 8:43 PM
Proud to be a part of this effort in @bloodjournals.hematology.org led by Andrew Hantel looking at the impact of inclusion criteria for AML clinical trials!
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
a very helpful consensus paper on how to define remission status in myelofibrosis post allo-HCT!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
October 14, 2025 at 9:11 PM
a very helpful consensus paper on how to define remission status in myelofibrosis post allo-HCT!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Check our work on disparities in MF outcomes led by @andrewthepalmer.bsky.social! We found:
-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well
www.nature.com/articles/s41...
-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well
www.nature.com/articles/s41...
October 6, 2025 at 9:46 PM
Check our work on disparities in MF outcomes led by @andrewthepalmer.bsky.social! We found:
-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well
www.nature.com/articles/s41...
-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well
www.nature.com/articles/s41...
Reposted by Anand Patel
How can clinicians identify patients with MPNs whose disease is in the accelerated or blast phase? 🩸
🎥 @anand-88-patel.bsky.social shares insight into this in an interview from the #MPNWorkshop2025:
👉 buff.ly/ygLFHa4 👈
#MPNsm #HemOnc #MedSky #HemeSky #BloodSky
🎥 @anand-88-patel.bsky.social shares insight into this in an interview from the #MPNWorkshop2025:
👉 buff.ly/ygLFHa4 👈
#MPNsm #HemOnc #MedSky #HemeSky #BloodSky
October 2, 2025 at 9:00 AM
How can clinicians identify patients with MPNs whose disease is in the accelerated or blast phase? 🩸
🎥 @anand-88-patel.bsky.social shares insight into this in an interview from the #MPNWorkshop2025:
👉 buff.ly/ygLFHa4 👈
#MPNsm #HemOnc #MedSky #HemeSky #BloodSky
🎥 @anand-88-patel.bsky.social shares insight into this in an interview from the #MPNWorkshop2025:
👉 buff.ly/ygLFHa4 👈
#MPNsm #HemOnc #MedSky #HemeSky #BloodSky
Back on inpatient leukemia service for 14 days!
Day 1- ziftomenib in R/R NPM1m AML
pubmed.ncbi.nlm.nih.gov/40997296/
Day 1- ziftomenib in R/R NPM1m AML
pubmed.ncbi.nlm.nih.gov/40997296/
September 30, 2025 at 1:13 AM
Back on inpatient leukemia service for 14 days!
Day 1- ziftomenib in R/R NPM1m AML
pubmed.ncbi.nlm.nih.gov/40997296/
Day 1- ziftomenib in R/R NPM1m AML
pubmed.ncbi.nlm.nih.gov/40997296/
Reposted by Anand Patel
In any other country, if federal agents fired upon journalists when unprovoked — what would we call it?
If federal agents marched down streets demanding papers — what would we say?
Authoritarianism — let’s not pretend it’s something else when it happens in our American cities.
If federal agents marched down streets demanding papers — what would we say?
Authoritarianism — let’s not pretend it’s something else when it happens in our American cities.
September 30, 2025 at 12:01 AM
In any other country, if federal agents fired upon journalists when unprovoked — what would we call it?
If federal agents marched down streets demanding papers — what would we say?
Authoritarianism — let’s not pretend it’s something else when it happens in our American cities.
If federal agents marched down streets demanding papers — what would we say?
Authoritarianism — let’s not pretend it’s something else when it happens in our American cities.
Informative paper on MECOMr AML highlighting we have a lot of work to do!
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia
MECOM rearrangements (MECOM-r) are acute myeloid leukaemia (AML)-defining, regardless of blast percentage or MECOM fusion partner. We sought to investigate if blast percentage or MECOM-r partner was ....
onlinelibrary.wiley.com
September 25, 2025 at 5:27 PM
Informative paper on MECOMr AML highlighting we have a lot of work to do!
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...
interesting study looking at the impact of various demographic features including SES in patients with AML in various eras of AML therapy
haematologica.org/article/view...
haematologica.org/article/view...
September 20, 2025 at 7:19 PM
interesting study looking at the impact of various demographic features including SES in patients with AML in various eras of AML therapy
haematologica.org/article/view...
haematologica.org/article/view...
Reposted by Anand Patel
This is what it looks like when ICE violates our First Amendment rights.
September 19, 2025 at 11:27 AM
This is what it looks like when ICE violates our First Amendment rights.
Reposted by Anand Patel
The current ACIP is not a credible committee. It pains me to say this, but do NOT listen to them for guidance on vaccines. I am an infectious disease doc and will be roundly ignoring their misinformed and anti-scientific guidelines.
Yesterday's spectacle was an insult to vaccinology and science.
Yesterday's spectacle was an insult to vaccinology and science.
September 19, 2025 at 11:17 AM
The current ACIP is not a credible committee. It pains me to say this, but do NOT listen to them for guidance on vaccines. I am an infectious disease doc and will be roundly ignoring their misinformed and anti-scientific guidelines.
Yesterday's spectacle was an insult to vaccinology and science.
Yesterday's spectacle was an insult to vaccinology and science.
a huge thanks to a patient of mine who was willing to share his story with @theaacr.bsky.social regarding being treated with Aza + Ven + Revumenib as part of the BEAT AML study and to advocate for cancer research funding!
cancerprogressreport.aacr.org/report/survi...
cancerprogressreport.aacr.org/report/survi...
Back on the Golf Course Rebuilding His Game, Thanks to a Clinical Study
Jack Moorman was diagnosed with acute myeloid leukemia at age 65. He participated in a clinical trial of a new targeted therapy called revumenib, which has kept his cancer in check.
cancerprogressreport.aacr.org
September 17, 2025 at 4:15 PM
a huge thanks to a patient of mine who was willing to share his story with @theaacr.bsky.social regarding being treated with Aza + Ven + Revumenib as part of the BEAT AML study and to advocate for cancer research funding!
cancerprogressreport.aacr.org/report/survi...
cancerprogressreport.aacr.org/report/survi...
a study in @bloodjournals.hematology.org illustrating that ASXL1 mutations in CML are a bad actor!
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
September 16, 2025 at 4:54 PM
a study in @bloodjournals.hematology.org illustrating that ASXL1 mutations in CML are a bad actor!
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Reposted by Anand Patel
Reading today’s big NYT Magazine story made me physically sick
It details how Trump & the men he put in charge of federal research—men like Jay Bhattacharya & RFK Jr—are dismantling cancer research
Not just the US vaccine system—they’re crushing cancer R&D
🎁Link
www.nytimes.com/2025/09/14/m...
It details how Trump & the men he put in charge of federal research—men like Jay Bhattacharya & RFK Jr—are dismantling cancer research
Not just the US vaccine system—they’re crushing cancer R&D
🎁Link
www.nytimes.com/2025/09/14/m...
How the Trump Administration Is Dismantling America’s Cancer-Research System
www.nytimes.com
September 14, 2025 at 1:32 PM
Reading today’s big NYT Magazine story made me physically sick
It details how Trump & the men he put in charge of federal research—men like Jay Bhattacharya & RFK Jr—are dismantling cancer research
Not just the US vaccine system—they’re crushing cancer R&D
🎁Link
www.nytimes.com/2025/09/14/m...
It details how Trump & the men he put in charge of federal research—men like Jay Bhattacharya & RFK Jr—are dismantling cancer research
Not just the US vaccine system—they’re crushing cancer R&D
🎁Link
www.nytimes.com/2025/09/14/m...